|5.29||+0.1700||+3.32%||Vol 76.95K||1Y Perf -4.66%|
|Nov 30th, 2023 15:59 DELAYED|
|- -||0.06 1.13%|
|Target Price||20.00||Analyst Rating||Strong Buy 1.00|
|Potential %||278.07||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||36.57||Earnings Rating||—|
|Market Cap||84.54M||Earnings Date||13th Dec 2023|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||13th Dec 2023|
|Estimated EPS Next Report||-0.18|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||75.20K|
|Avg. Monthly Volume||104.92K|
|Avg. Quarterly Volume||93.61K|
BriaCell Therapeutics Corp. (NASDAQ: BCTX) stock closed at 5.29 per share at the end of the most recent trading day (a 3.32% change compared to the prior day closing price) with a volume of 76.95K shares and market capitalization of 84.54M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 0 people. BriaCell Therapeutics Corp. CEO is William Williams.
The one-year performance of BriaCell Therapeutics Corp. stock is -4.66%, while year-to-date (YTD) performance is 21.05%. BCTX stock has a five-year performance of %. Its 52-week range is between 3.67 and 8.1, which gives BCTX stock a 52-week price range ratio of 36.57%
BriaCell Therapeutics Corp. currently has a PE ratio of -3.40, a price-to-book (PB) ratio of 7.93, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -0.95%, a ROC of -2.22% and a ROE of -1.43%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from BriaCell Therapeutics Corp., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.18 for the next earnings report. BriaCell Therapeutics Corp.’s next earnings report date is 13th Dec 2023.
The consensus rating of Wall Street analysts for BriaCell Therapeutics Corp. is Strong Buy (1), with a target price of $20, which is +278.07% compared to the current price. The earnings rating for BriaCell Therapeutics Corp. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BriaCell Therapeutics Corp. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BriaCell Therapeutics Corp. has a Buy technical analysis rating based on Technical Indicators (ADX : 29.34, ATR14 : 0.35, CCI20 : 169.23, Chaikin Money Flow : 0.33, MACD : 0.05, Money Flow Index : 66.58, ROC : 34.43, RSI : 62.97, STOCH (14,3) : 97.96, STOCH RSI : 1.00, UO : 65.33, Williams %R : -2.04), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BriaCell Therapeutics Corp. in the last 12-months were: Jamieson Bondarenko (Buy at a value of $363 640)
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.